Lambe H A, Hopper K D, Matthews Y L
College of Medicine, Pennsylvania State University, Hershey 17033.
Radiology. 1992 Jul;184(1):145-8. doi: 10.1148/radiology.184.1.1609071.
The use of informed consent before intravenous administration of contrast material remains a controversial issue. It involves explaining the risks of intravenous contrast material and obtaining the patient's permission for its use. All physician groups who had billed Pennsylvania Blue Shield for at least three intravenous contrast material-enhanced procedures performed in 1989 were surveyed. Informed consent was obtained from at least some patients by about two-thirds of physician groups before using intravenous contrast material, regardless of whether it was ionic or nonionic. Nonradiologists were more likely to obtain informed consent before the use of ionic contrast material than radiologists. Regardless of specialty, practices associated with larger hospitals (greater than 250 beds), larger physician groups (greater than 10), or a university used informed consent less often than smaller physician groups or those associated with a smaller hospital or a private practice. Though results may be affected by regional variation or increased usage since previous surveys, the use of informed consent before the intravenous injection of contrast material is a common practice; it is obtained in the majority of patients.
在静脉注射造影剂前使用知情同意书仍然是一个有争议的问题。这涉及到解释静脉造影剂的风险并获得患者使用造影剂的许可。对所有在1989年至少为宾夕法尼亚蓝盾保险公司开具过三次静脉造影剂增强检查账单的医生团体进行了调查。大约三分之二的医生团体在使用静脉造影剂前至少从一些患者那里获得了知情同意,无论造影剂是离子型还是非离子型。与放射科医生相比,非放射科医生在使用离子型造影剂前更有可能获得知情同意。无论专业如何,与大型医院(超过250张床位)、大型医生团体(超过10人)或大学相关的医疗机构比小型医生团体或与小型医院或私人诊所相关的医疗机构更少使用知情同意书。尽管结果可能受到地区差异或自上次调查以来使用量增加的影响,但在静脉注射造影剂前使用知情同意书是一种常见做法;大多数患者都获得了知情同意。